Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal

After banking two $50 million venture rounds about a year apart, Surrozen is ready to hit Wall Street. The company plans to go public via SPAC in a deal worth up to $212 million.

The regenerative medicine player is combining with Consonance-HFW Acquisition Corp., a special purpose acquisition company sponsored by affiliates of Consonance Capital Management. If all goes to plan, the deal will close in the third quarter and the combined company will receive $92 million from the SPAC, as well as $120 million through a private round. It will list on the Nasdaq under the ticker “SRZN.”